Trial · NCT03095066
Participant flow72
How many started, completed or left each group, period by period.
1 to 20 of 72
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study (Baseline to Week 12) | STARTED | Overall Study: Stage 1 Placebo/Stage 2 Placebo or Stage 1 Placebo/Stage 2 AVP-786 | 83 | |
| Overall Study (Baseline to Week 12) | STARTED | Overall Study: Stage 1 AVP-786/Stage 2 AVP-786 | 85 | |
| Overall Study (Baseline to Week 12) | STARTED | Stage 1: Placebo | 0 | |
| Overall Study (Baseline to Week 12) | STARTED | Stage 1: Placebo Non-responders to Stage 2: Placebo | 0 | |
| Overall Study (Baseline to Week 12) | STARTED | Stage 1: Placebo Non-responders to Stage 2: AVP-786 | 0 | |
| Overall Study (Baseline to Week 12) | STARTED | Stage 1: Placebo Responders to Stage 2: Placebo | 0 | |
| Overall Study (Baseline to Week 12) | STARTED | Stage 1: Placebo Responders to Stage 2: AVP-786 | 0 | |
| Overall Study (Baseline to Week 12) | STARTED | Stage 1 and 2: AVP-786 | 0 | |
| Overall Study (Baseline to Week 12) | COMPLETED | Overall Study: Stage 1 Placebo/Stage 2 Placebo or Stage 1 Placebo/Stage 2 AVP-786 | 58 | |
| Overall Study (Baseline to Week 12) | COMPLETED | Overall Study: Stage 1 AVP-786/Stage 2 AVP-786 | 68 | |
| Overall Study (Baseline to Week 12) | COMPLETED | Stage 1: Placebo | 0 | |
| Overall Study (Baseline to Week 12) | COMPLETED | Stage 1: Placebo Non-responders to Stage 2: Placebo | 0 | |
| Overall Study (Baseline to Week 12) | COMPLETED | Stage 1: Placebo Non-responders to Stage 2: AVP-786 | 0 | |
| Overall Study (Baseline to Week 12) | COMPLETED | Stage 1: Placebo Responders to Stage 2: Placebo | 0 | |
| Overall Study (Baseline to Week 12) | COMPLETED | Stage 1: Placebo Responders to Stage 2: AVP-786 | 0 | |
| Overall Study (Baseline to Week 12) | COMPLETED | Stage 1 and 2: AVP-786 | 0 | |
| Overall Study (Baseline to Week 12) | NOT COMPLETED | Overall Study: Stage 1 Placebo/Stage 2 Placebo or Stage 1 Placebo/Stage 2 AVP-786 | 25 | |
| Overall Study (Baseline to Week 12) | NOT COMPLETED | Overall Study: Stage 1 AVP-786/Stage 2 AVP-786 | 17 | |
| Overall Study (Baseline to Week 12) | NOT COMPLETED | Stage 1: Placebo | 0 | |
| Overall Study (Baseline to Week 12) | NOT COMPLETED | Stage 1: Placebo Non-responders to Stage 2: Placebo | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03095066/flow